Literature DB >> 10371635

Venous angiomas with arteriovenous shunts: report of three cases and review of the literature

.   

Abstract

OBJECTIVE AND IMPORTANCE: In spite of recent recognition of the benign nature of venous angioma (VA), only limited information is available on the clinical features of VA with arteriovenous shunt (AVS). The purpose of this study was to elucidate the clinical profile of VA with AVS. CLINICAL PRESENTATION AND INTERVENTION: We describe three patients having a VA with AVS and review the clinical features of 31 patients reported in the literature, including our three patients. The patients included 12 women and 19 men, ranging in age from 18 to 54 years. Seven patients (22.6%) presented with intracranial hemorrhage, and none of 16 patients developed a new or recurrent hemorrhage (mean follow-up period, 11 months). Treatment was conservative in 14 patients, lobectomy or partial resection of the VA in 6, removal of hematoma in 4, operation only for coexisting aneurysm or arteriovenous malformation in 4, and not known in 3. The outcome was reported as good recovery in 19 patients, persistent neurological deficits in 2, death or deterioration not related to the VA in 3, and not known in 7.
CONCLUSION: Although there remains some uncertainty as to the clinical features of VA with AVS, its prognosis seems to be essentially as benign as that of VA without AVS. Thus, conservative treatment is recommend except for patients with a large hematoma or with a coexisting arteriovenous malformation or a symptomatic, accessible cavernous angioma, which may be treated by surgical intervention. Further collection of data is required to establish definite treatment guidelines.

Entities:  

Year:  1999        PMID: 10371635     DOI: 10.1097/00006123-199906000-00100

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  8 in total

1.  Postcontrast susceptibility-weighted imaging: a novel technique for the detection of arteriovenous shunting in vascular malformations of the brain.

Authors:  Bharathi D Jagadeesan; Josser E Delgado Almandoz; Tammie L S Benzinger; Christopher J Moran
Journal:  Stroke       Date:  2011-09-22       Impact factor: 7.914

2.  Venous angiomas.

Authors:  Sepideh Amin-Hanjani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-06

3.  Developmental venous anomalies with capillary stain: a subgroup of symptomatic DVAs?

Authors:  Luca Roccatagliata; René van den Berg; Michael Soderman; Anne Boulin; Stéphanie Condette-Auliac; Georges Rodesch
Journal:  Neuroradiology       Date:  2011-06-11       Impact factor: 2.804

4.  Accuracy of susceptibility-weighted imaging for the detection of arteriovenous shunting in vascular malformations of the brain.

Authors:  Bharathi D Jagadeesan; Josser E Delgado Almandoz; Christopher J Moran; Tammie L S Benzinger
Journal:  Stroke       Date:  2010-11-18       Impact factor: 7.914

5.  Developmental venous anomaly (DVA) with arterial component: a rare cause of intracranial haemorrhage.

Authors:  Ismail Oran; Yilmaz Kiroglu; Alaattin Yurt; Fisun Demircivi Ozer; Feridun Acar; Tayfun Dalbasti; Baki Yagci; Akif Sirikci; Cem Calli
Journal:  Neuroradiology       Date:  2008-09-12       Impact factor: 2.804

6.  Atypical developmental venous anomaly associated with single arteriovenous fistula and intracerebral hemorrhage: a case demonstrated by superselective angiography.

Authors:  Jae Eun Roh; Sang-Hoon Cha; Seung Young Lee; Min Hee Jeon; Bum Sang Cho; Min Ho Kang; Kyung Soo Min
Journal:  Korean J Radiol       Date:  2011-12-23       Impact factor: 3.500

7.  Spontaneous regression of a symptomatic developmental venous anomaly with capillary stain.

Authors:  Takeru Hirata; Satoru Miyawaki; Satoshi Koizumi; Yu Teranishi; Osamu Ishikawa; Nobuhito Saito
Journal:  Interv Neuroradiol       Date:  2021-08-04       Impact factor: 1.764

Review 8.  Developmental Venous Anomaly: Benign or Not Benign.

Authors:  Rie Aoki; Kittipong Srivatanakul
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-06-01       Impact factor: 1.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.